All In Biotech

Drug Trial Radar · NCT05555732

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,233 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,233

Actual

Start

Jan 11, 2023

Primary completion

May 11, 2029

Study completion May 11, 2031

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca; Merck Sharp & Dohme LLC
First posted
Sep 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

Conditions

  • Metastatic Non Small Cell Lung Cancer

Interventions

  • Datopotamab DeruxtecanDrug

    Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

  • PembrolizumabDrug

    Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

  • PemetrexedDrug

    Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

  • CarboplatinDrug

    Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

  • CisplatinDrug

    Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival Based on Blinded Independent Central Review in All Randomized ParticipantsTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 43 months
  2. Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants who are TROP2 NMR positiveTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 43 months
  3. Overall Survival in All Randomized ParticipantsTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 76 months
  4. Overall Survival in All Randomized Participants who are TROP2 NMR positiveTime frame: From randomization until disease progression or death (whichever occurs first), up to approximately 76 months

Locations

260 sites in 29 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center Pc

    Daphne, Alabama

  • Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Arizona Oncology Associates, Pc - Nahoa

    Prescott Valley, Arizona

  • Hoag Memorial Hospital Prebyterian

    Newport Beach, California

  • Compassionate Cancer Care Medical Group

    Riverside, California

  • Sansum Clinic

    Santa Barbara, California

  • Ronald Reagan UCLA Medical Center

    Santa Monica, California

  • UCHealth Memorial Hospital

    Colorado Springs, Colorado

  • Florida Cancer Specialists - South

    Fort Myers, Florida

  • Cancer Specialist of North Florida

    Jacksonville, Florida

  • Cancer Care Centers of Brevard, Inc.

    Palm Bay, Florida

  • Woodlands Medical Specialists, Pa

    Pensacola, Florida

  • Florida Cancer Specialists-North

    St. Petersburg, Florida

  • Emory University - Winship Cancer Institute Wci

    Atlanta, Georgia

  • Illinois Cancer Specialists

    Niles, Illinois

  • American Oncology Partners of Maryland

    Bethesda, Maryland

  • Maryland Oncology Heamtology P.A.

    Columbia, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute; Inv Drg Svc Pharm

    Boston, Massachusetts

  • Dana Farber Cancer Institute At St. Elizabeth'S Medical Center

    Brighton, Massachusetts

  • Dana Farber Brigham Cancer Center

    Foxborough, Massachusetts

  • Dana Farber At Milford Regional Cancer Center

    Milford, Massachusetts

  • Dana Farber/Bwcc in Affiliation With South Shore Hospital

    South Weymouth, Massachusetts

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Regional Cancer Care Associates LLC

    Hackensack, New Jersey

  • North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists- New Hyde Park

    New Hyde Park, New York

  • North Shore Hematology Oncology Associates

    Patchogue, New York

  • North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists

    Port Jefferson Station, New York

  • North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists - Bronx

    The Bronx, New York

  • Texas Oncology, P.A.

    McAllen, Texas

  • Ut Health San Antonio

    San Antonio, Texas

  • Texas Oncology, P.A.

    Sugar Land, Texas

  • Texas Oncology-Tyler

    Tyler, Texas

  • Utah Cancer Specialists IHO Corp

    Salt Lake City, Utah

  • Providence Regional Cancer System

    Lacey, Washington

  • VA Puget Sound Health Care System

    Seattle, Washington

  • Centro de Investigaciones Medicas y Desarrollo LC SRL

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Buenos Aires, Argentina

  • Fundacion CENIT para la investigacion en Neurociencias

    Ciudad Autonoma de Buenos Aire, Argentina

  • Hospital de La Comunidad

    Mar del Plata, Argentina

Showing 40 of 260 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.